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BRAF inhibitors can extend progression-free and overall survival in melanoma patients
whose tumors harbor mutations in BRAF. However, the majority of patients eventually
develop resistance to these drugs. Here we show that BRAF mutant melanoma cells that
have developed acquired resistance to BRAF inhibitors display increased oxidative meta-
bolism and increased dependency on mitochondria for survival. Intriguingly, the increased
oxidative metabolism is associated with a switch from glucose to glutamine metabolism
and an increased dependence on glutamine over glucose for proliferation. We show that
the resistant cells are more sensitive to mitochondrial poisons and to inhibitors of glutami-
nolysis, suggesting that targeting specific metabolic pathways may offer exciting therapeu-
tic opportunities to treat resistant tumors, or to delay emergence of resistance in the first-
line setting.
ª 2015 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction and is one of themost common characteristics of solid tumors.One of the hallmarks of cancer is metabolic reprogramming,
whichprovides thenutrientsandredoxpotentialneeded tosup-
port continuous proliferation and growth in environments that
are deprivedof oxygenandnutrients (Cantor andSabatini, 2012;
Ward andThompson, 2012). Aerobic glycolysis (theWarburg ef-
fect) converts glucose to lactate regardless of oxygenavailability100.
981.
ac.uk (E. Gottlieb), richard
3
Elsevier B.V. on behalf o
://creativecommons.org/liInmany cases, these traits are driven directly by oncogenes and
tumor suppressors, altering glucose and glutaminemetabolism
in tumor cells (Cantor and Sabatini, 2012). For example, onco-
genic BRAF and oncogenic RAS regulate expression of genes in
the glycolysis, pentose phosphate and glutaminolysis path-
ways, changing the dependence of cells on different carbon
sources (Haq et al., 2013; Ying et al., 2012)..marais@cruk.manchester.ac.uk (R. Marais).
f Federation of European Biochemical Societies. This is an open
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types driven by specific genetic alterations. About 45% of
cutaneous melanomas harbor mutations in BRAF, a protein
kinase that is part of the RAS/RAF/MEK/ERK pathway and
which regulates cell proliferation and survival (Solit et al.,
2006; Wan et al., 2004). The most common mutation in
BRAF is a glutamine for valine substitution at position 600
(V600E), which produces an active kinase that drives consti-
tutive MEK/ERK signaling and cell proliferation (Davies et al.,
2002; Dhomen and Marais, 2009; Wan et al., 2004). Drugs that
inhibit V600EBRAF, such as vemurafenib and dabrafenib, or
drugs that inhibit MEK such as trametinib and cobimetinib
can extend overall survival in melanoma patients whose tu-
mors harbor a V600EBRAF mutation (Hauschild et al., 2012;
Lito et al., 2013; Menzies and Long, 2013; Sosman et al.,
2012). Unfortunately however, intrinsic and secondary/ac-
quired resistance limits the overall response and therapeutic
benefit of these personalized medicines (Girotti et al., 2014;
Heidorn et al., 2010; Johannessen et al., 2010, 2013;
Maertens et al., 2013; Montagut et al., 2008; Nazarian et al.,
2010; Poulikakos et al., 2011; Shi et al., 2011; Straussman
et al., 2012). Many studies have shown that resistance to
BRAF targeted therapies is mediated by alterations in the
signaling pathways that control cell growth. Up-regulation
of receptor tyrosine kinase signaling, or mutations in NRAS
or MEK have all been shown to regulate resistance, as have
upregulation or alternative splicing of V600EBRAF itself (Lito
et al., 2013). Similarly, increased release of growth factors
by the stromal cells, or alterations to transcription factors
that control expression of signaling components can
mediate resistance (Straussman et al., 2012; Wilson et al.,
2012).
In other diseases, it has emerged that metabolic rewiring
can also contribute to resistance. For example, lapatinib/
trastuzumab-resistant breast cancer cells display a depen-
dency on glucose metabolism and the ER-stress network
(Komurov et al., 2012; Zhao et al., 2011). Moreover, melanoma
cells display aerobic glycolysis and use glutamine to
replenish tricarboxylic acid (TCA) cycle metabolites (Hall
et al., 2013; Scott et al., 2011). V600EBRAF regulates glycolysis
genes and oxidative metabolism in some melanoma cells
through the transcription factors MITF and PGC1a, and ERK
signaling suppresses the oxidative phenotype (Haq et al.,
2013; Vazquez et al., 2013). Furthermore, vemurafenib-
resistant cell lines display increased mitochondrial respira-
tion, rendering them more vulnerable to oxidative stress-
mediated cell death (Corazao-Rozas et al., 2013). Here we
investigate how metabolism is changed in melanomas that
develop acquired resistance to BRAF inhibitors to identify
new therapeutic targets for patients who relapse on first-
line targeted therapies.2. Material and methods
2.1. Cell lines and reagents
General reagents were purchased from Sigma (St. Louis, MO,
USA), except PLX4720, which was from 3way Pharm(Shanghai, China). A375, Colo829, SKMEL5 and G361 cells
were purchased from the ATCC and maintained in RPMI or
DMEM, supplemented with 10% FBS, 1 mM sodium pyruvate,
2 mM glutamine and 1% penicillin/streptomycin. To generate
BRAF inhibitor resistant clones cells were cultured in
increasing concentrations of PLX4720 (0.1e1 mM) and the resis-
tant clones were maintained in 1 mM PLX4720 thereafter.2.2. Metabolic assays
Oxygen consumption ratewasmeasuredwith the optical fluo-
rescent oxygen/hydrogen sensor XFe96 Seahorse analyzer.
Briefly cells (25,000/well) were incubated overnight and
washed into unbuffered DMEM with an adjusted pH of 7.4 ac-
cording to the manufacturer’s instructions. The mitochondria
stress kit was used to measure OCR responses using the
following concentrations: 1 mM oligomycin, 2 mM FCCP, 1 mM
rotenone and 1 mM antimycin A. The data was normalized to
protein content by sulforhodamine B (SRB) staining.
Lactate secretion was analyzed using Biovison Lactate kits.
Briefly cells (25,000/well) were cultured overnight and incu-
bated in glucose- and glutamine-free DMEM/10% FBS plus
1mMpyruvate for one hour prior to incubation in fullmedium
for one hour. 10 mL supernatant were used for the analysis and
raw values were normalized to protein content.2.3. Mitochondrial morphology
Cells (2 105 in 6 cm glass-bottomed plates) were stainedwith
Mitotracker Green (100 nM; Invitrogen) and the nuclei were
counter-stained with Hoechst (5 mg/mL; Invitrogen) and then
visualized on a Nikon A1R confocal microscope.2.4. Metabolic fluxes and exchange rates
Cells were incubated for 48 h in full RPMImedia and exchange
rates for glucose, lactate, pyruvate, glutamine and glutamate
were calculated by comparing the peak area for each metabo-
lite in full RPMImedia kept under the same conditions for 48 h
without cells and considering the average cell number during
the culture time. Metabolites in 20 mL culture media were
extracted (6 biological replicates per experiment; 3 indepen-
dent experiments) in 980 mL ice cold acetonitrile:methanol:-
water (3:5:2), and centrifuged (10 min, 16,000 g) at 4 C for
LC-MS analysis (Chaneton et al., 2012).
For intracellular labeling experiments, cells were incu-
bated in full RPMI media for 24 h in the presence of 10 mM
U-13C6 glucose or 2 mM U-
13C5 glutamine. The cells were
washed twice with PBS and intracellular metabolites
extracted in acetonitrile:methanol:water (3:5:2) at 1 ml per
106 cells. Samples were analyzed by LC-MS using a Sequant
ZIC-pHILIC column (2.1 mm  150 mm, 5 mmpolymeric beads,
guard column Sequant ZIC-pHILIC guard peek
2.1 mm  20 mm, Millipore) using formic acid, water, and
acetonitrile as components of the mobile phase. Mass spec-
trometry was performed in a Thermo Scientific Exactive
Benchtop LC/MS Orbitrap Mass spectrometer (Chaneton
et al., 2012).
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Tumors were formalin-fixed and analyzed as previously
described (Girotti et al., 2013). Sample preparation for mito-
chondrial staining was performed with antigen retrieval (so-
dium citrate pH6.0). Positive and negative controls were
included in each experiment. Whole faced sections of paired
melanoma samples from patients corresponding to tumor tis-
sue before and after vemurafenib treatment were analyzed.
Samples were scored blind and a staining score was provided
for each section, where score ¼ S(% of cells with intensity
4 * 4) þ (% of cells with intensity 3 * 3) þ (% of cells with inten-
sity 2 * 2) þ (% of cells with intensity 1 * 1); where 0 ¼ no stain-
ing, 1 ¼ light, 2 ¼ moderate 3 ¼ intense and 4 ¼ very intense
staining. The p value (2-sided) for the Wilcoxon matched-
pairs signed rank test is 0.0313.
2.6. siRNA experiments
Melanoma cells were trypsinized and counted (1  106 cells/
well) and transfected with Lipofectamine 3000 and a non tar-
geting control siRNA (AllStars negative Control #SI03650318,
QIAGEN) or two different siRNAs targeting PGC1a
(Hs_PPARGC1A_2 and 6 FlexiTube siRNA; #SI00101031 and
#SI02639833; all from QIAGEN). Two rounds of transfection
were performed within 48 h prior to cells being used for RNA
analysis or drug response experiments.
2.7. Short-term growth inhibition assays
Cells (103/well) were seeded into 96-well plates and incubated
with various dilutions of PLX4720, BPTES, phenformin, bufor-
min, metformin or 2DG for 72 h. Cell viability was determined
by SRB staining and resultswere normalized to untreated con-
trols after background subtraction.
2.8. Long-term cell proliferation assays
Cells (5 104/well) were seeded into 6-well plates and cultured
for 10 days with the indicated drugs and then stained with
crystal violet. Quantification was performed by dissolving
the crystal violet in 500 mL methanol.
2.9. Mouse xenografts
All procedures involving animals were approved by CRUK
Manchester Institute’s Animal Welfare and Ethical Review
Body, in accordance with the Animals (Scientific Procedures)
Act 1986, carried out under license PPL/70/7701 and reported
according to the NC3Rs ARRIVE guidelines. Five to six week
old female nude mice were injected subcutaneously with
1 106 A375 or A375/R cells. Tumors were allowed to establish
to 100e150 mm3, size matched, and then the mice were
randomly allocated to groups of 8 animals. No blinding was
used in the treatment schedules for these studies. Based on
literature precedents, groups of 8 animals were used, to pro-
vide sufficient animals per cohort to provide statistically sig-
nificant data, whilst keeping animal numbers to a
minimum. Treatment was administered by oral gavage daily
with vehicle (5% DMSO, 95% water) or 45 mpk (mg per kilo)PLX4720. For the glutaminolysis inhibition study, 12.5 mpk
BPTES or vehicle was injected intraperitoneally every two
days. Tumor size was determined by caliper measurements
of tumor length, width, and depth, and volumewas calculated
as volume ¼ 0.5236  length  width  depth (mm). In accor-
dance with our license to perform animal experiments, ani-
mals were excluded from the experiments if they displayed
signs of distress, excessive bodyweight loss (>20%) or illness.
2.10. Statistical analysis
Statistics were performed with GraphPad Prism version 6.0b
(GraphPad Software, San Diego, CA, USA). Data are presented
asmean SD ormean SEM. The student’s t-test orWilcoxon
matched-pairs signed rank test was performed and statistical
significance values are 0.05.3. Results
3.1. BRAF inhibitor resistance is associated with
increased mitochondrial biogenesis and oxidative
metabolism
We have reported that BRAF mutant melanoma cells develop
drug resistance when grown in the presence of BRAF inhibi-
tors (Girotti et al., 2013). For the studies reported here, we
used BRAF mutant A375 and Colo829 melanoma cell clones
(A375/R and Colo829/R respectively) that were over 100-fold
less sensitive to the BRAF inhibitor PLX4720 than their respec-
tive parental cells (Supplemental Figure 1A). Staining with
MitoTracker Green revealed that the mitochondria in the
resistant cells were elongated compared to those in the
parental cells (Figure 1A) and we found that the resistant cells
were more sensitive than the parental cells to the biguanide
mitochondrial poisons phenformin, metformin and buformin
(Supplemental Figure 1B). Thus BRAF inhibitor resistant cells
displayed altered mitochondrial morphology and increased
dependence on mitochondrial function, so we examined
metabolism in these cells.
The resistant cells displayed increased expression of PGC1a
(Figure 1B), a transcription coactivator that regulates mito-
chondrial biogenesis (Puigserver and Spiegelman, 2003). We
show that depletion of PGC1a by siRNA (Supplemental
Figure 1C) reversed mitochondrial elongation in the resistant
cells, but did not affect mitochondrial morphology in the
parental cells, linking PGC1a expression to the altered mito-
chondrial morphology (Figure 1C, Supplemental Figure 1D).
Consistent with increased mitochondrial biogenesis, we
show increased expression of the mitochondrial respiratory
chain genes MT-CO2, MT-CYB, and MT-ATP6/8 in the resistant
cells (Figure 1DeF) and confirmed that MT-CO2 protein
expression was increased in the resistant cells
(Supplemental Figure 2A, B). Critically, we show that MT-
CO2 expression was increased in melanomas from 7 patients
who presented resistance to vemurafenib (p ¼ 0.03; Figure 1G,
Supplemental Figure 2C), demonstrating the clinical relevance
of our findings.
Mitochondrial elongation is associated with increased
oxidative metabolism (Gomes et al., 2011) and we show that
Figure 1 e BRAF inhibitor resistant melanoma cells exhibit increased mitochondrial mass and oxidative metabolism. (A) Photomicrographs
showing mitochondrial morphology (Mitotracker Green) and nuclei (Hoechst, blue) in A375, Colo829, A375/R and Colo829/R cells. (B) PGC1a
levels in A375, Colo829, A375/R and Colo829/R cells. Error bars represent SEM of at least two independent experiments with 3 biological
replicates. ****p< 0.0001. (C) Photomicrographs showing mitochondrial morphology (Mitotracker Green) in A375, Colo829, A375/R and
Colo829/R cells after silencing with siRNA control (siCtrl) or two different siRNA probes against PGC1a. (DeF) MT-CO2 (D), MT-CYB (E),
and MT-ATP6/8 (F) mRNA levels in A375, Colo829, A375/R and Colo829/R cells. Error bars represent SEM of at least two independent
experiments with 3 biological replicates. *p< 0.05, **p< 0.01, ***p< 0.001 and ****p< 0.0001. (G) The box-plot showing quantification of
MT-CO2 staining in 7 paired samples from patients before and after emergence of vemurafenib resistance; *p< 0.05, and test (Wilcoxon Signed-
Rank Test). (H) Oxygen consumption rate (OCR) changes in response to mitochondrial function modulators in A375, Colo829, A375/R and
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were substantially increased compared to their drug-
sensitive parental cells (Figure 1H). We also observed
decreased lactate secretion (Figure 1I) and increased intracel-
lular ATP (Figure 1J). Note that the increased intracellular ATP
was not due to increased proliferation, as the resistant cells
actually grew more slowly than the parental cells
(Supplemental Figure 2D).
Next, we examined these responses in SKMEL5 and G361
cells, because these BRAFmutantmelanoma cells are intrinsi-
cally resistant to BRAF inhibitors and arew10 fold less sensi-
tive to PLX4720 than A375 and Colo829 (Supplemental
Figure 2E). Accordingly, continual exposure of SKMEL5 and
G361 cells to PLX4720 only modestly affected their sensitivity
to this compound (Supplemental Figure 2E), did not cause
increased basal or maximal respiration (Figure 1K) and did
not cause decreased lactate secretion or increased intracel-
lular ATP (Figure 1L, M). Thus, PLX4720 did not alter oxidative
metabolism in intrinsically resistant cells.
3.2. BRAF inhibition reduces glycolytic flux
The data above show that BRAF inhibitor-resistant cells pre-
sent increased mitochondrial mass, increased dependence
on mitochondrial function and increased oxidative respira-
tion. Consistent with these observations, when parental
A375 and Colo829 cells were forced to depend on oxidative
metabolism by culturing in galactose as the only carbon
source, PGC1a expression increased (Figure 2A) and the cells
were more resistant to PLX4720 (Figure 2B). Thus, switching
to oxidative metabolism mediates resistance to BRAF inhibi-
tors, so we examined glucose consumption in the resistant
cells. We added uniformly labeled 13C (U-13C) glucose to the
cells and measured intracellular metabolites and observed
lower levels of glucose in the resistant than parental cells
(Figure 2C). Similarly, we detected lower levels of intracellular
glucose-6-phosphate (Figure 2D) and lactate (Figure 2E) in the
resistant cells and accordingly, the resistant cells consumed
less glucose and pyruvate, and they secreted less lactate
(Figure 2FeH). Critically, the A375/R and Colo829/R cells were
more tolerant of glucose starvation and less sensitive to inhi-
bition of glycolysis by the small molecule inhibitor 2-
deoxyglucose (2DG; Figure 2I, J). Note that the SKMEL5/R and
G361/R cells were no less sensitive to glucose starvation and
nomore resistant to 2DG (Figure 2I, J) than their parental cells,
demonstrating that these effects do not occur in intrinsically
resistant cells.
3.3. PLX4720-resistant cells display increased
glutaminolysis
Thus, resistant cells are less dependent on glucose for pro-
liferation, and since recent studies have established thatColo829/R cells (n [ 3). (IeJ) Lactate secretion (I) and intracellular ATP
represent SEM of at least two independent experiments with 3 biological r
consumption rate (OCR) changes in response to mitochondrial function mo
(LeM) Lactate secretion (L) and intracellular ATP levels (M) in SKMEL5,
least two independent experiments with 3 biological replicates. n.s.: not sigglutamine is an important alternative carbon source for tu-
mor growth, we examined glutamine dependency in these
cells. To analyze the glutamine carbon flux, we incubated
the cells with uniformly labeled 13C (U-13C) glutamine and
show that intracellular glutamine was increased in the
resistant cells (Figure 3A). Consistently, the resistant cells
consumed more glutamine (Figure 3B) and were more sen-
sitive to glutamine starvation (Figure 3C). Note however
that the SKMEL5/R and G361/R cells were no more sensitive
to glutamine starvation than their parental clones
(Figure 3C).
These data suggest that cells with acquired resistance
are more reliant on glutamine, and accordingly we
observed increased glutamate levels in resistant cells
(Figure 3D). Consistent with this, we observed increased
expression of GLS, a glutaminase that converts glutamine
to glutamate (Supplemental Figure 3A), in the resistant
cells (Figure 3E). Note that GLS expression did not increase,
but actually decreased in SKMEL5/R and G361/R cells
(Figure 3E). Commensurate with these results, we detected
a lower contribution from glucose to citrate (identified by
the changes in the levels of Mþ3 mass isotopomer of pyru-
vate (Pyrþ3) and of the Mþ2 mass isotopomer of citrate
(Citþ2) using U-13C glucose) in the resistant cells
(Figure 3F).
3.4. Inhibition of glutaminolysis blocks the growth of
PLX4720-resistant tumors
Thus, glutamine is a major carbon source for cells with ac-
quired resistance, so we treated the cells with BPTES (Bis-2-
(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide), a
small molecule GLS inhibitor. BPTES did not affect oxygen
consumption rate (OCR) in parental cells but significantly
reduced basal and maximal respiration in A375/R and
Colo829/R cells (Figure 4A, B). Furthermore, BPTES reduces
ATP levels in resistant but not parental cells (Figure 4C).
Commensurate with these findings, the in vitro growth of the
parental cells was not affected by BPTES, whereas BPTES
inhibited the growth of the resistant cells (Figure 4D, E).
Notably, the growth inhibitory effects of BPTES on the resis-
tant cells were partially rescued by dimethyl-a-ketoglutarate,
a cell-permeable a-ketoglutarate analogue that enters the glu-
taminolysis pathway below the level of GLS (Figure 4D, E;
Supplemental Figure 3A). This confirms that the growth-
inhibitory effects of BPTES were mediated by inhibition of
glutaminolysis.
Next, we tested BPTES in vivo by growing A375/R cells as
xenografts in immunocompromised mice. The A375/R tu-
mors were insensitive to PLX4720, and although their
growth was delayed by BPTES, PLX4720 and BPTES did not
cooperate to inhibit their growth any further (Figure 4F).
We next tested BPTES in parental A375 xenografts. Inlevels (J) in A375, Colo829, A375/R and Colo829/R cells. Error bars
eplicates. **p< 0.01, ***p< 0.001, ****p< 0.0001. (K) Oxygen
dulators in SKMEL5, SKMEL5/R, G361 and G361/R cells (n[ 3).
G361, SKMEL5/R and G361/R cells. Error bars represent SEM of at
nificant.
Figure 2 e BRAF inhibitor resistant melanoma cells display decreased glycolytic flux. (A) Graph showing PGC1a mRNA levels in A375 and
Colo829 cells grown for 5 days in medium containing glucose or galactose as the sole carbon source. Error bars represent SEM of at least two
independent experiments with 3 biological replicates. ****p< 0.0001. (B) Graph showing A375 cell growth (sulforhodamine B) in glucose or
galactose containing medium in the presence of increasing concentrations of PLX4720 for 72 h. (CeE) Graphs showing glucose (C), glucose-6-
phosphate (D), and lactate (E) levels in A375, Colo829, A375/R and Colo829/R cells labeled with U-13C6 glucose. The graphs show mean ± SD
(n [ 6) and similar results were observed in two independent experiments. Legend displays the different isotopomers. 13C1: one carbon atom
labeled; 13C2 e
13C6: two to six carbon atoms labeled. Glucose and glucose-6-phosphate are 6-carbon molecules hence
13C6 labeling (gray). Lactate
is a 3-carbon molecule hence the 13C3 labeling (red). Endogenous metabolites are unlabeled and shown in white. (FeH) Graphs showing glucose
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Figure 3 e BRAF inhibitor resistant melanoma cells show increased glutamine metabolism. (A) Graph showing intracellular glutamine levels in
A375, A375/R, Colo829 and Colo829/R cells labeled with U-13C5 glutamine. Legend displays isotopomer distribution.
13C1: one carbon atom
labeled; 13C2e
13C5: two to five carbon atoms labeled. Glutamine is a 5-carbon molecule hence
13C5 labeling (blue). Endogenous glutamine is
unlabeled and shown in white. (B) Graph showing glutamine consumption (extracellular exchange rates) in A375 and A375/R cells. Data are
representative of three independent studies and displayed as mean ± SD of n[ 6. (C) Graph showing growth (sulforhodamine B) of A375, A375/
R, Colo829, Colo829/R, SKMEL5, SKMEL5/R, G361 and G361/R cells in medium containing 0.5 mM glutamine for 72 h. Data are presented
relative to medium containing 2 mM glutamine. Error bars represent SEM of three independent experiments with 3 biological replicates.
*p< 0.05, ns: non-significant. (D) Graph showing intracellular glutamine levels in A375, A375/R, Colo829 and Colo829/R cells labeled with
U-13C5 glutamine. Data are a representative experiment of mean ± SD of n [ 6. Similar results were observed in two independent experiments.
Legend displays isotopomer distribution. 13C1: one carbon atom labeled;
13C2 to
13C5: two to five carbon atoms labeled. Glutamate is a 5-carbon
molecule hence 13C5 labeling (blue). Endogenous glutamate is unlabeled and shown in white. (E) Graph showing GLS mRNA levels in A375,
A375/R, Colo829, Colo829/R, SKMEL5, SKMEL5/R, G361 and G361/R cells. Three independent experiments with n[ 3 were performed and
results display mean ± SEM. *p< 0.05, **p< 0.01, and ****p<0.0001. (F) Ratio of intracellular citrate (CitD2) to pyruvate (PyrD3) in A375 and
A375/R cells.
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insensitive to BPTES, but their growth was delayed by
PLX4720 (Figure 4G). Importantly, BPTES enhanced the
anti-tumor activity of PLX4720 against parental A375 tu-
mors, by not only inducing regression, but by also suppress-
ing the emergence of resistance.(F), pyruvate, (G) and lactate (H) consumption (extracellular exchange rate
independent studies and displayed as mean ± SD of n [ 6. (I) Growth (su
SKMEL5/R, G361 and G361/R cells in medium containing 1 mM glucose
10 mM glucose (dotted line). Error bars represent SEM of at three indepen
n.s.: non-significant. (J) Growth of A375, A375/R, Colo829, Colo829/R, S
increasing concentrations 2DG for 72 h (n [ 3).4. Discussion
It has previously been reported that V600EBRAF inhibition in
melanoma cells suppresses expression of glycolytic enzymes,
leading to reduced glucose consumption and growth inhibi-
tion (Parmenter et al., 2014). We show that increased) in A375 and A375/R cells. Data are representative of three
lforhodamine B) of A375, A375/R, Colo829, Colo829/R, SKMEL5,
for 72 h. Data are expressed relative to growth in medium containing
dent experiments with 3 biological replicates. *p< 0.05, **p< 0.01,
KMEL5, SKMEL5/R, G361 and G361/R cells in the presence of
Figure 4 e Glutaminolysis inhibition diminishes oxidative metabolism and cell viability of BRAF inhibitor resistant melanoma cells. (A, B)
Oxygen consumption rate (OCR) changes in response to mitochondrial function modulators in A375 and A375/R cells (A), and in Colo829 and
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 7 3e8 480
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 7 3e8 4 81oxidative metabolism contributes to resistance to BRAF in-
hibitors, an observation also reported by Corazao-Rozas
et al. (Corazao-Rozas et al., 2013), suggesting that these drugs
place cancer cells under selective pressure to restore oxida-
tive metabolism and hence proliferation. Ectopic expression
of Q61KNRAS in the presence of BRAF inhibitors restores
expression of glycolytic enzymes in V600EBRAF melanoma
cells (Parmenter et al., 2014), but we show that melanoma
cells that acquired resistance through continuous exposure
to BRAF inhibitors, are less dependent on glucose, but rather
switch to glutamine as amajor carbon source. Specifically, we
show that glutamine uptake is increased and GLS is upregu-
lated. The shift to glutamine metabolism appears to allow
the resistant cells to sustain survival and proliferation
despite reduced flux of glucose-derived carbon into the TCA
cycle (Metallo et al., 2012; Vander Heiden et al., 2011). Thus,
glutaminolysis effectively sustains TCA cycle metabolite
levels (anaplerosis) and presumably provides nitrogen for
nucleotide biosynthesis.
An increase in glutamine consumption may also provide
other advantages. It was recently reported that highly invasive
ovarian cancer cells aremore dependent on glutamine for sur-
vival than cells that present low invasion (Yang et al., 2014)
and we recently found that BRAF inhibitor resistant mela-
noma cells are more invasive than sensitive cells (Sanchez-
Laorden et al., 2014). Thus, the resistant cells may switch to
glutamine not only to sustain proliferation; it may also
contribute to other hallmarks of cancer such as invasion and
metastasis.
Our findings are consistent with studies showing that
cancer cells, including melanoma, display metabolic flexi-
bility and can adapt to new/stressful growth conditions
(Cantor and Sabatini, 2012; Dang et al., 2009; Frezza et al.,
2011; Scott et al., 2011). They are also consistent with data
showing that PGC1a expression and oxidative phosphoryla-
tion are elevated in some V600EBRAF mutant melanomas
(Vazquez et al., 2013) and that BRAF inhibition increases
PGC1a expression in melanoma cell lines (Haq et al., 2013).
PGC1a is a key regulator of mitochondrial biosynthesis and
PGC1a is constitutively upregulated in resistant cells. This
is coincident with mitochondrial elongation, increasedmito-
chondrial mass and increased oxidative phosphorylation,
and accordingly, the cells show increased dependence on
the mitochondria for survival. Thus, in line with another
study demonstrating that PLX4720-resistant melanoma cell
lines are more sensitive to metformin and phenformin
(Yuan et al., 2013), our data suggests that directly targeting
the mitochondria could offer therapeutic opportunities in
resistant tumors.Colo829/R cells (B), treated with DMSO (control) or BPTES (2 mM) for 18
showing ATP levels in A375, A375/R, Colo829 and Colo829/R cells treated
of at least two independent experiments with three biological replicates eac
days) growth of A375 and A375/R cells (D) and in Colo829 and Colo829/R
dimethyl-a-KG (dmKM; 5 mM) or both. The graphs below the images sho
two independent experiments with three biological replicates each; ****p<0
xenografts in nude mice (n [ 8 per group) treated with PLX4720 (45 mpk
ManneWhitney-U test *p< 0.05. (G) Graph showing growth of A375 xeno
p.o. daily) or BPTES (12.5 mpk IP every second day) or both. ManneWhCritically, the resistant cells are less sensitive to glucose
starvation and inhibition of glycolysis, but more sensitive
to glutamine starvation and inhibition of glutaminolysis.
Inhibition of glutaminolysis can suppress the growth of
Burkitt’s lymphoma and other cancers driven by MYC (Le
et al., 2012; Wise et al., 2008; Xiang et al., 2015), and here
we show that BRAF inhibitor resistant melanoma cells
are also more sensitive to glutaminase inhibition, suggest-
ing that glutaminase may also be a therapeutic target in
the resistant tumors. PGC1a is important for glutamine
metabolism in ERBB2-positive breast cancer (McGuirk
et al., 2013) and glutamine transporters are proposed ther-
apeutic targets in melanoma (Wang et al., 2014), high-
lighting the therapeutic potential of this metabolic
pathway. Accordingly, we show that resistant cells remain
sensitive, albeit weakly, to BPTES, but more importantly
that BPTES enhances the anti-tumor activity of BRAF inhi-
bition, presumably by suppressing switching to glutamine
metabolism.
Developing effective treatments to delay or overcome
resistance in melanoma is a clinical and biological chal-
lenge due to the complexity of the multiple mechanisms
of resistance that sustain MAPK/ERK signaling in the resis-
tant cells. Recent studies have shown that BRAF regulates
metabolism (Corazao-Rozas et al., 2013; Hall et al., 2013;
Parmenter et al., 2014) and our results here show that a sub-
set of melanoma cells that develop resistance to BRAF in-
hibitors switch from a glycolytic to oxidative phenotype
and use glutamine as a major carbon source. We posit
that combining BRAF inhibitors with drugs that target gluta-
minolysis or mitochondrial function may be an effective
strategy to treat or prevent resistance to BRAF inhibitors
in melanoma patients.Contributions
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